Answers are grounded in this paper and cite their sources.
Background/Objectives: Biologics targeting type-2 inflammation represent maintenance medications that reduce asthma and chronic obstructive pulmonary disease (COPD) exacerbation risk. Whether biologics may be used to treat acute exacerbations, specifically administered during the exacerbation itself, is an emerging paradigm. The purpose of this review was to identify and characterize biologics treating acute asthma or COPD. Methods: This was a rapid, systematic review of biologics to treat acute exacerbations of asthma or COPD. Databases searched included Ovid MEDLINE, Ovid Embase, and Scopus. Experimental and observational studies were eligible. Records were independently screened and appraised by four investigators and extracted by one investigator. Quality appraisal was conducted using RoB 2 and JBI instruments for experimental studies and case reports, respectively. Results: Two randomized controlled studies and 30 case reports/series (37 patients) were eligible for inclusion. Benralizumab and omalizumab were the most reported biologics (n = 10 and n = 9 studies, respectively). The ABRA trial noted benralizumab reduced 90-day treatment failure, though the COPD-HELP trial evaluating mepolizumab did not observe mortality or readmission reductions. Case report-level data often described near-fatal or life-threatening asthma exacerbations treated in intensive care units; all patients with reported survival outcomes (n = 36) survived. Conclusions: Emerging evidence suggests biologics administered during exacerbations may improve acute care outcomes, predominantly in asthma; evidence in COPD is limited. The current evidence should be viewed as exploratory; further randomized trials evaluating biologic administration, particularly in COPD, are warranted.
No takes yet. Share an insight, caveat, or question.
Vu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: